How Analysts Feel About Bluebird Bio Incorporated (NASDAQ:BLUE) After Increase in Sellers?

September 17, 2017 - By Vivian Park

 How Analysts Feel About Bluebird Bio Incorporated (NASDAQ:BLUE) After Increase in Sellers?

Investors sentiment decreased to 1.29 in Q4 2016. Its down 0.19, from 1.48 in 2016Q3. It is negative, as 33 investors sold bluebird bio Inc shares while 51 reduced holdings. 30 funds opened positions while 78 raised stakes. 45.73 million shares or 4.13% more from 43.91 million shares in 2016Q3 were reported.
75 were accumulated by Ironwood Limited Liability Com. 8,400 were reported by Cornerstone Capital Mngmt Hldgs Ltd Com. Cqs Cayman Lp invested 0.2% of its portfolio in bluebird bio Inc (NASDAQ:BLUE). Moreover, Westpac has 0% invested in bluebird bio Inc (NASDAQ:BLUE) for 30,851 shares. Great West Life Assurance Company Can invested in 3,509 shares. 453,354 were reported by Arrowpoint Asset Management Ltd Limited Liability Company. Alliancebernstein L P holds 0% in bluebird bio Inc (NASDAQ:BLUE) or 57,220 shares. Eventide Asset Mgmt Ltd has invested 2.36% in bluebird bio Inc (NASDAQ:BLUE). 83,887 were reported by California State Teachers Retirement. Ameritas Partners Incorporated accumulated 3,409 shares. Savings Bank Of New York Mellon Corporation has 0% invested in bluebird bio Inc (NASDAQ:BLUE). Da Davidson Comm holds 1,150 shares or 0% of its portfolio. Legal General Grp Public Limited, United Kingdom-based fund reported 13,587 shares. Woodstock Corp owns 9,090 shares. Blackrock Japan, Japan-based fund reported 387 shares.

The stock of Bluebird Bio Incorporated (NASDAQ:BLUE) registered an increase of 1.53% in short interest. BLUE’s total short interest was 7.62 million shares in September as published by FINRA. Its up 1.53% from 7.50M shares, reported previously. With 866,300 shares average volume, it will take short sellers 9 days to cover their BLUE’s short positions. The short interest to Bluebird Bio Incorporated’s float is 18.82%.

The stock decreased 0.19% or $0.25 on September 15, reaching $131.6. About 1.13 million shares traded or 27.93% up from the average. bluebird bio Inc (NASDAQ:BLUE) has risen 112.34% since September 17, 2016 and is uptrending. It has outperformed by 95.64% the S&P500.

bluebird bio, Inc. is a clinical-stage biotechnology company. The company has market cap of $6.00 billion. The Firm is focused on developing gene therapies for severe diseases and cancer. It currently has negative earnings. With its lentiviral gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas.

bluebird bio Inc (NASDAQ:BLUE) Ratings Coverage

Among 22 analysts covering bluebird bio (NASDAQ:BLUE), 13 have Buy rating, 2 Sell and 7 Hold. Therefore 59% are positive. bluebird bio had 55 analyst reports since August 11, 2015 according to SRatingsIntel. The stock has “Hold” rating by Morgan Stanley on Wednesday, June 14. BMO Capital Markets maintained the stock with “Buy” rating in Thursday, August 31 report. The rating was maintained by JP Morgan with “Overweight” on Saturday, August 22. The firm has “Buy” rating given on Thursday, December 1 by Maxim Group. The firm has “Neutral” rating by TH Capital given on Monday, February 6. The rating was maintained by Cantor Fitzgerald with “Sell” on Monday, June 5. The stock of bluebird bio Inc (NASDAQ:BLUE) has “Buy” rating given on Thursday, September 29 by Maxim Group. The stock has “Buy” rating by Jefferies on Tuesday, July 4. The company was downgraded on Monday, December 7 by Bank of America. Standpoint Research downgraded the stock to “Reduce” rating in Friday, June 16 report.

More notable recent bluebird bio Inc (NASDAQ:BLUE) news were published by: which released: “Kite Pharma Acquired – bluebird bio Remains Undervalued” on August 28, 2017, also with their article: “Surging bluebird bio Stock Attracts Fresh Batch of Call Buyers” published on September 14, 2017, published: “Is bluebird bio Overvalued?” on September 11, 2017. More interesting news about bluebird bio Inc (NASDAQ:BLUE) were released by: and their article: “Why bluebird bio Inc and Juno Therapeutics Inc Shot Higher Today” published on August 28, 2017 as well as‘s news article titled: “Why bluebird bio Inc Jumped Higher Today” with publication date: August 30, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.